BioSpace News Archive

Aquaporin A/S announced the Annual Report for the period January 1 to December 31, 2023.

Sebia announced that it has received 510 clearance from the U.S. Food and Drug Administration for CAPILLARYS 3 DBS devices. Our solution is intended for the detection of normal hemoglobins and abnormal hemoglobins in blood from human newborn collected on filter paper.

MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM dedicated to enhancing survival of patients with cancer, announces the initiation of coverage of its stock by Gilbert Dupont.

Innate Pharma SA announced the filing of its 2023 Universal Registration Document for the year ending December 31, 2023 with the French market authority “Autorité des Marchés Financiers” on April 4, 2024.

Photocure ASA, The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider will present a corporate overview and host 1-on-1 meetings with investors at the 23rd Annual Needham Healthcare Conference being held virtually April 8-11, 2024.

HUTCHMED Limited announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Predicine, Inc. A leading precision oncology company, announced that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that, on March 28, 2024, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of the Company’s common stock to two newly hired employees.

I-Mab announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

BPGbio, Inc. today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.